Comparison of body composition changes between atazanavir/ritonavir and lopinavir/ritonavir each in combination with tenofovir/emtricitabine in antiretroviral-naïve patients with hiv-1 infection

Clinical Drug Investigation

Volumn 34, Issue 4, 2014, Pages 287-296

  Moyle, Graeme J ^a   Hardy, Hélène ^b   Farajallah, Awny ^b   Degrosky, Michelle ^b   McGrath, Donnie ^b  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ATAZANAVIR PLUS RITONAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LEPTIN; LOPINAVIR PLUS RITONAVIR; TRIACYLGLYCEROL; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; DEOXYCYTIDINE; DRUG COMBINATION; EMTRICITABINE; LOPINAVIR; LOPINAVIR-RITONAVIR DRUG COMBINATION; OLIGOPEPTIDE; PHOSPHONIC ACID DERIVATIVE; PYRIDINE DERIVATIVE; RITONAVIR; TENOFOVIR DISOPROXIL;

ADULT; ARTICLE; BODY COMPOSITION; BODY FAT; BODY MASS; CD4 LYMPHOCYTE COUNT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INTRAABDOMINAL FAT; LIPID STORAGE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS FAT; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WAIST HIP RATIO; WEIGHT GAIN; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECTS; HIV INFECTIONS; PHOTON ABSORPTIOMETRY; YOUNG ADULT;

ABSORPTIOMETRY, PHOTON; ADENINE; ADULT; ANTI-HIV AGENTS; BODY COMPOSITION; DEOXYCYTIDINE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; LOPINAVIR; MALE; OLIGOPEPTIDES; ORGANOPHOSPHONATES; PYRIDINES; RITONAVIR; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 84898812359     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-014-0175-4     Document Type: Article

References (40)

1. Macallan DC, Noble C, Baldwin C, et al. Prospective analysis of patterns of weight change in stage IV human immunodeficiency virus infection. Am J Clin Nutr. 1993;58(3):417-24.
2. Crum-Cianflone N, Tejidor R, Medina S, Barahona I, Ganesan A. Obesity among patients with HIV: the latest epidemic. AIDS Patient Care STDS. 2008;22(12):925-30. doi: 10.1089/apc 2008.0082.
3. Crum-Cianflone NF, Roediger M, Eberly LE, et al. Obesity among HIV-infected persons: impact of weight on CD4 cell count. AIDS. 2010;24(7):1069-72. doi: 10.1097/QAD.0b013e328337fe01.
4. Janiszewski PM, Ross R, Despres JP, et al. Hypertriglyceridemia and waist circumference predict cardiovascular risk among HIV patients: a cross-sectional study. PLoS One. 2011;6(9):e25032. doi: 10.1371/journal.pone.0025032.
5. Lemieux I, Pascot A, Couillard C, et al. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation. 2000;102(2):179-84.
6. Mocroft A, Sabin CA, Youle M, et al. Changes in AIDS-defining illnesses in a London clinic, 1987-1998. J Acquir Immune Defic Syndr. 1999;21(5):401-7.
7. Smit E, Skolasky RL, Dobs AS, et al. Changes in the incidence and predictors of wasting syndrome related to human immunodeficiency virus infection, 1987-1999. Am J Epidemiol. 2002;156(3):211-8.
8. Carr A, Ritzhaupt A, Zhang W, et al. Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adults. AIDS. 2008;22(17):2313-21. doi: 10.1097/QAD.0b013e328315a7a5.
9. Haubrich RH, Riddler SA, DiRienzo AG, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS. 2009;23(9):1109-18. doi: 10.1097/QAD.0b013e32832b4377.
10. Podzamczer D, Ferrer E, Sanchez P, et al. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr. 2007;44(2):139-47. doi: 10.1097/QAI.0b013e31802bf122.
11. Tungsiripat M, Bejjani DE, Rizk N, et al. Rosiglitazone improves lipoatrophy in patients receiving thymidine-sparing regimens. AIDS. 2010;24(9):1291-8. doi: 10.1097/QAD.0b013e328339e274.
12. Dube MP, Parker RA, Tebas P, et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS. 2005;19(16):1807-18.
13. Mallon PW, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS. 2003;17(7):971-9. doi: 10.1097/01.aids.0000060348.78202. 74.
14. Squires KE, Young B, Dejesus E, et al. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients. AIDS. 2010;24(13):2019-27. doi: 10.1097/QAD.0b013e32833bee1b.
15. Jemsek JG, Arathoon E, Arlotti M, et al. Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients. Clin Infect Dis. 2006;42(2):273-80. doi: 10.1086/498505.
16. Koethe JR, Lukusa A, Giganti MJ, et al. Association between weight gain and clinical outcomes among malnourished adults initiating antiretroviral therapy in Lusaka, Zambia. J Acquir Immune Defic Syndr. 2010;53(4):507-13. doi: 10.1097/QAI.0b013e3181b32baf.
17. Madec Y, Szumilin E, Genevier C, et al. Weight gain at 3 months of antiretroviral therapy is strongly associated with survival: evidence from two developing countries. AIDS. 2009;23(7):853-61. doi: 10.1097/QAD. 0b013e32832913ee.
18. Amorosa V, Synnestvedt M, Gross R, et al. A tale of 2 epidemics: the intersection between obesity and HIV infection in Philadelphia. J Acquir Immune Defic Syndr. 2005;39(5):557-61.
19. Scherzer R, Heymsfield SB, Lee D, et al. Decreased limb muscle and increased central adiposity are associated with 5-year all-cause mortality in HIV infection. AIDS. 2011;25(11):1405-14. doi: 10.1097/QAD.0b013e32834884e6.
20. Worm SW, Friis-Moller N, Bruyand M, et al. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. AIDS. 2010;24(3):427-35. doi: 10.1097/QAD. 0b013e328334344e.
21. Joy T, Keogh HM, Hadigan C, et al. Relation of body composition to body mass index in HIV-infected patients with metabolic abnormalities. J Acquir Immune Defic Syndr. 2008;47(2):174-84. doi: 10.1097/QAI.0b013e31815b0792.
22. Currier J, Scherzer R, Bacchetti P, et al. Regional adipose tissue and lipid and lipoprotein levels in HIV-infected women. J Acquir Immune Defic Syndr. 2008;48(1):35-43. doi: 10.1097/QAI.0b013e318164227f.
23. Wohl D, Scherzer R, Heymsfield S, et al. The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men. J Acquir Immune Defic Syndr. 2008;48(1):44-52. doi: 10.1097/QAI.0b013e31816d9ba1.
24. Moyle G. Metabolic issues associated with protease inhibitors. J Acquir Immune Defic Syndr. 2007;45(Suppl 1):S19-26. doi: 10.1097/QAI.0b013e31806007ed.
25. McComsey GA, Kitch D, Sax PE, et al. Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s. Clin Infect Dis. 2011;53(2):185-96. doi: 10.1093/cid/cir324.
26. Vrouenraets SM, Wit FW, Fernandez Garcia E, et al. Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naive HIV-1-infected patients. HIV Med. 2011;12(10):620-31. doi: 10.1111/j.1468-1293.2011.00941.x.
27. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 2008;372(9639):646-55. doi: 10.1016/S0140-6736(08)61081-8.
28. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr. 2010;53(3):323-32. doi: 10.1097/QAI.0b013e3181c990bf.
29. Croom KF, Dhillon S, Keam SJ. Atazanavir: a review of its use in the management of HIV-1 infection. Drugs. 2009;69(8):1107-40. doi: 10.2165/00003495-200969080-00009.
30. Noor MA, Parker RA, O'Mara E, et al. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS. 2004;18(16):2137-44.
31. Mallolas J, Podzamczer D, Milinkovic A, et al. Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study. J Acquir Immune Defic Syndr. 2009;51(1):29-36. doi: 10.1097/QAI.0b013e31819a226f.
32. Stanley TL, Joy T, Hadigan CM, et al. Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients. AIDS. 2009;23(11):1349-57. doi: 10.1097/QAD.0b013e32832ba904.
33. Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology. 2004;145(5):2273-82. doi: 10.1210/en.2003-1336.
34. Grunfeld C, Pang M, Shigenaga JK, et al. Serum leptin levels in the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1996;81(12):4342-6.
35. Kosmiski LA, Bacchetti P, Kotler DP, et al. Relationship of fat distribution with adipokines in human immunodeficiency virus infection. J Clin Endocrinol Metab. 2008;93(1):216-24. doi: 10.1210/jc.2007-1155.
36. Nagy GS, Tsiodras S, Martin LD, et al. Human immunodeficiency virus type 1-related lipoatrophy and lipohypertrophy are associated with serum concentrations of leptin. Clin Infect Dis. 2003;36(6):795-802. doi: 10.1086/367859.
37. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev. 2000;21(6):697-738.
38. Wajchenberg BL, Giannella-Neto D, da Silva ME, Santos RF. Depot-specific hormonal characteristics of subcutaneous and visceral adipose tissue and their relation to the metabolic syndrome. Horm Metab Res. 2002;34(11-12):616-21. doi: 10.1055/s-2002-38256.
39. Sam S, Haffner S, Davidson MH, et al. Hypertriglyceridemic waist phenotype predicts increased visceral fat in subjects with type 2 diabetes. Diabetes Care. 2009;32(10):1916-20. doi: 10.2337/dc09-0412.
40. Brown TT, Xu X, John M, et al. Fat distribution and longitudinal anthropometric changes in HIV-infected men with and without clinical evidence of lipodystrophy and HIV-uninfected controls: a substudy of the Multicenter AIDS Cohort Study. AIDS Res Ther. 2009;6:8. doi: 10.1186/1742-6405-6-8.